59611-54-0 Usage
Uses
Used in Pharmaceutical Industry:
4-CHLORO-5-METHOXY-2-METHYL-QUINOLINE is used as a pharmaceutical agent for its potential antimicrobial properties, serving as a candidate for the development of new antibiotics to combat resistant bacterial strains.
Used in Antimalarial Applications:
In the field of antimalarial drug development, 4-CHLORO-5-METHOXY-2-METHYL-QUINOLINE is utilized as a potential antimalarial agent, offering a new avenue for treating malaria and possibly contributing to overcoming drug-resistant strains of the Plasmodium parasite.
Used in Organic Synthesis:
4-CHLORO-5-METHOXY-2-METHYL-QUINOLINE is used as a building block in organic synthesis for creating a variety of other organic compounds, leveraging its unique structural features to form novel chemical entities with potential applications in various industries.
Used in Drug Development:
4-CHLORO-5-METHOXY-2-METHYL-QUINOLINE is employed in the research and development of new drugs, where its properties are harnessed to design and synthesize pharmaceuticals with improved efficacy and selectivity for treating various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 59611-54-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,6,1 and 1 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 59611-54:
(7*5)+(6*9)+(5*6)+(4*1)+(3*1)+(2*5)+(1*4)=140
140 % 10 = 0
So 59611-54-0 is a valid CAS Registry Number.
59611-54-0Relevant academic research and scientific papers
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety
Abe, Yoshito,Kayakiri, Hiroshi,Satoh, Shigeki,Inoue, Takayuki,Sawada, Yuki,Inamura, Noriaki,Asano, Masayuki,Aramori, Ichiro,Hatori, Chie,Sawai, Hiroe,Oku, Teruo,Tanaka, Hirokazu
, p. 4062 - 4079 (2007/10/03)
Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]
